institute for glycomics · 2019. 5. 20. · remarkable science cancer the australian centre for...

2017

Annual ReportInstitute for Glycomics

Contents

About the institute 2

Director’s report 3

Institute highlights 5

Remarkable scienceCancer 7

Infectious disease 8

Translation & commercialisation 8

Internationalisation 8

Research highlights 10

Facilities 15

Publications 17

2017 Grants 23

Remarkable peopleInstitute organisation 24

Members of the institute 26

Research highlights 28

Financial Summary 29

2017 Graduates 30

2017 Institute/visiting speakers 31

Remarkable supportOur supporters 32

VisionTo be a world-leader in the discovery and development of drugs and vaccines through the application of innovative multidisciplinary science in a unique research environment.

Mission StatementFighting diseases of global impact through discovery and translational science.

Annual Report 2017 | 1

About the InstituteThe Institute for Glycomics is one of Australia’s flagship biomedical research institutes.

Established in 2000, through investment from Griffith University and the Queensland State Government, we strive to be world leaders in developing next generation drugs, vaccines and diagnostics for diseases of global impact.

Our advantage is our glycoscience-focused approach towards drug, vaccine and diagnostic technology discovery and development using world-leading scientific expertise and dedication to discovering preventions and cures for a number of human diseases including infectious diseases and cancers. Our approach brings together outstanding researchers in various areas of chemistry, biology and biophysics focussed on translational research that will have a positive impact on human health.

The Institute boasts some of the world’s most renowned research leaders and state-of-the-art facilities. This rich research environment provides exceptional postgraduate education programs for the nation’s future scientists.

We are one of Australia’s flagship multidisciplinary biomedical research institutes.

The Institute plays an integral role as part of the emerging Gold Coast Health and Knowledge Precinct (GCHKP) - a vibrant community of ideas, life and innovation.

The institute engages with industry, other premier research institutes, philanthropic organisations and governments from across the globe to build human capital to provide healthcare solutions to address the most intractable diseases.

>200 research and support members

>A$10 million external research income per annum

>100 peer reviewed publications each year

>1500 citations

2 | Institute for Glycomics

Director’s Report

2017 was an exciting year for our Institute with a number of discoveries, from both our drug and vaccine research programs, progressing into pre-clinical and human clinical trials. These discoveries seek to tackle some of the most challenging human diseases, including malaria, viral-induced arthritis and sepsis as detailed in this report. The Institute’s mission is to be a translational medical research institute and these trials reinforce our mission.

The Institute continued to grow through recruitment of both staff and students as well as the establishment of two major exciting initiatives within the Institute.

In recognition of our unique approach in cancer research we established the Australian Centre for Cancer Glycomics (A2CG) through major investment from both the University and philanthropy. This Centre brings together the Institute’s established cancer research groups and new research groups that have a focus on characterising the changes in the carbohydrate language on cancer cell surfaces. Characterisation of these changes will bring new direction in both drug and vaccine development to deliver cancer specific therapies.

Our other exciting major initiative was founded on the Institute’s long-term relationship with the Hannover Medical School (Medizinische Hochschule Hannover) and a new partnership with the Fraunhofer Institute for Experimental Toxicology and Medicine (Fraunhofer ITEM). This initiative, the international Consortium for Anti-Infective Research (iCAIR) was awarded a major international grant from the Fraunhofer Society, Germany and the research program tackles several respiratory infectious diseases such as influenza, croup and bacterial meningitis. The multi-million dollar grant, the first Fraunhofer grant of this type in Australia, has enabled the establishment of this international consortium that will advance drug candidates through pre-clinical studies to produce sufficient proof-of concept data to attract pharmaceutical industry investment.

Apart from researcher exchange and joint student supervision this initiative will bring advanced infectious disease models, discovered in the Fraunhoher ITEM, that enable us to evaluate our drug candidates in living human lung tissue (human precision cut lung slices). The long-term objective of this consortium is to establish a Fraunhofer Centre for Anti-infective Research within the Institute that will serve as a hub for like-minded research groups and centres in Australia and the region that wish to access Fraunhofer technology that will be established in the Institute.

Fighting Diseases of Global impactThe Institute is committed to discoveries that can be translated to better treatments, bringing a healthier future to our global community.

CANCER

• Colon Cancer

• Breast cancer

• Leukaemia

• Lung cancer

• Lymphoma

• Melanoma

• Head and neck cancer

• Ovarian cancer

• Prostate cancer

• Rare cancers

• Stomach cancer

INFECTIOUS DISEASE

• Malaria

• Chronic infections

• Hand, foot & Mouth

• Dengue

• Ross river

• Chikungunya and other emerging alphaviruses

• HIV

• Meliodosis

• Strep a/rheumatic heart disease

• RSV

• Croup/parainfluenza

• Middle ear infections

• Influenza

• Zika


This Centre brings together the Institute’s established cancer research groups and new research groups that have a focus on characterising the changes in the carbohydrate language on cancer cell surfaces.

Our community supporters and donors have played such a critical role for us in being able to continue to support our researchers and human clinical trials. While I could provide numerous examples of such support, I have chosen two highlights that are representative of community support. The first is the significant support from Rotary in raising funds to support our malaria trials. The Institute has established a strong partnership with Rotary to financially support our human clinical trials. This partnership is essential for us to advance our vaccine development program and the Institute is very grateful for Rotary’s support.

The other example is the continuing support of our Women in Glycomics program by the Institute’s Glycomics Circle. Some years ago the Institute identified the need to proactively support early career female researchers maintaining a career path in glycomics research. During 2017, the Circle raised substantial funds that have been used to offer both scholarships and travel grants to early career female researchers. This support is critical to enable our early career female researchers to support their studies and research and has been very successful in supporting the careers of both domestic and international early career female researchers in the Institute.

I am extremely grateful to all of our supporters for the continuing financial support as well as their enthusiasm for the research that we do in the Institute. I would also like to thank our staff and students for their incredible work and in telling our remarkable story.

Professor Mark von ItzsteinDirector

| Institute for Glycomics4

Institute highlights

200MEMBERS

40+DISEASESimpacted by Institute research AUSTRALIAN CENTRE

FOR CANCER GLYCOMICS

the only centre of its kind in Australia

$1 for $1IN PHILANTHROPIC

FUNDING SUPPORTS our research

2 DRUG AND

AUSTRALIA’S FIRSTPartnership Fraunhofer ITEM in infectious disease

Over

VACCINE candidates preparing to enter clinical trials

2

3 MAJOR NEW TECHNOLOGY co-development programs with industry partners underway

INCOME SOURCES FOR 2017

Research grant funding $9.046 millIndustry & other support

$9.418 mill


DOING REMARKABLE SCIENCE Our success rests on our capacity to advance basic research and translation.

Our strategy builds on our existing strengths and emerging opportunities.| Institute for Glycomics6

Remarkable science

Cancer The Australian Centre for Cancer Glycomics (A2CG) brings together the Institute’s cancer research projects and was established in May 2017.

This unique national resource dedicated to cancer glycomics research, is the result of significant funding by Griffith University.

The state of the art equipment and infrastructure, coupled with the brightest scientific talent in the field of cancer glycoproteomics, makes the A2CG an exciting hub of truly revolutionary research. The Institute for Glycomics and the A2CG are taking a highly integrated, systematic approach to identifying important cancer biomarkers and tumour-associated carbohydrate antigens (TACAs), underpinned by a strategic focus geared towards translational outcomes.

As the only institute of its kind in the southern hemisphere, the Institute for Glycomics is already an epicentre of glycomics research globally and houses many world-leading carbohydrate researchers. A project with the vision and scale of the A2CG requires substantial human resource, technical knowledge and specialisation. Significant investment by Griffith University has attracted the world’s brightest scientific minds, including new research teams led by Professor Nicolle Packer and Associate Professor Daniel Kolarich.

By combining core expertise and infrastructure, the A2CG is a world-class platform for mapping the cancer glycome, and translating these discoveries into novel diagnostics and therapies.

Griffith’s New Australian Centre for Cancer Glycomics

The Institute for Glycomics at the University’s Gold Coast campus is now home to the newly-established Australian Centre for Cancer Glycomics.

Local Federal Member and Minister for Trade, Tourism and Investment the Honourable Steven Ciobo MP toured the biomedical research Institute that will work towards the discovery of new cancer diagnostics, drugs and vaccines which will have global impact.

Glycomics is the study of the carbohydrates that appear on the surface of both healthy and diseased cells. Human cells are covered with a thick layer of carbohydrate chains known as glycans that provide unique cell sugar signatures and form the cell’s sugar coat.

These signatures play a pivotal role in the life of a cell not the least being their part in determining cancer growth and development.

The Centre is partnering with a range of other national and international institutions including the Chris O’Brien Lifehouse, one of the largest academic cancer centres which is providing access to patient data and thousands of stored cancer tissue samples.

The newly formed Centre has also initiated a major collaboration with Distinguished Professor Judith Clements AC, Scientific Director of the Australian Prostate Cancer Research Centre, and has also engaged local surgeons, such as Gold Coast oncology surgeon Dr Nic Crampton, in establishing a dedicated Melanoma Cell Bank.


Infectious DiseaseInfectious diseases pose some of the world’s biggest health challenges. The programs the Institute research encompass bacterial, viral, parasitic and fungal infectious diseases, with an interest on diseases of relevance to public health in tropical environments.

International partnership in Anti-Infective Research

Researchers from Griffith’s Institute for Glycomics are partnering with researchers from the Fraunhofer Institute for Toxicology and Experimental Medicine and the Hannover Medical School for a project called ‘iCAIR—Fraunhofer International Consortium for Anti-Infective Research’ to develop new anti-infective drugs.

The project aims to discover new treatments to combat respiratory viruses including influenza virus and respiratory infection-causing bacteria and fungi. Infectious diseases and antibiotic resistance are a global, and potentially deadly threat.

Previously effective antibiotics are becoming less and less effective against multi-resistant bacteria, and there is an urgent need to develop new drugs and treatments to combat infection.

The biggest hurdle in developing new medications is getting them from the laboratory into clinical trials, bridging the gap from the discovery of new agents to their development by the pharmaceutical industry into potential medications.

iCAIR will be working on the development of anti-infective therapies that take new treatment options all the way from the identification of potentially beneficial substances to the preclinical proof of concept. The alliance will establish a development platform that will cover all the steps of a targeted drug development process, from identifying potential points of attack, right through to drug design and efficacy testing.

Translation and Commercialisation of world-leading basic science

The Institute has invested heavily in the translation and commercialisation of its drug and vaccine discovery science.

Partnering with industry to guide the development of its drug and vaccine technologies is critical to ensuring those technologies are well positioned for success in a competitive global market.

Educating and providing funding opportunities to Institute researchers in translation and commercialisation, and in particular for the Institute’s Early Career Researchers, has been a core strategy of the Institute’s Executive over the past several years. Through the Glycomics Industry Fund (GIF), a pilot proof of concept fund that requires a cash co-commitment from industry to develop a novel idea or project, 4 new partnerships were established with industry in 2017, of which two GIF grants were awarded to Institute Early Career Researchers. Two of these partnerships were with large US-based organisations, providing greater access to US grant opportunities and investment.

Through investment in translational infrastructure and business personnel, the Institute has developed a robust platform for translation and commercialisation. It has pursued licence and co-development deal strategy that has helped to expedite the development of several of its drug and vaccine candidate technologies.

By the end of 2017, the Institute had progressed four drug and vaccine technologies to Phase 1 or Phase 2 human clinical trials. Importantly, for two of the technologies, co-development and licence deals had already been negotiated with industry, with a deal on a third technology underway in December 2017. This deal strategy has been a successful in 1) providing industry engagement in a two-way sharing of expertise 2) ensuring the Institute utilises the full breadth of its research expertise in developing a technology, and 3) attracting significant ongoing contract funding while establishing a path to market for the technology.

By way of example, a major vaccine licence and co-development program negotiated with Chinese biopharma company, Olymvax in 2016, gained significant momentum in 2017 with five Institute personnel appointed to the project and an additional 2 Olymvax personnel working in the Institute as part of the establishment of joint laboratories for vaccine development. The model for this successful international cooperation for commercial technology development is being rolled out in China for the development and commercialisation of other Institute technologies.

Internationalisation

Searching globally to identify the world’s best international organisations for partnering with the view to perform excellent translational science has been a key strategy for the Institute’s Executive over the past several years. The development of new tools to expedite the drug discovery process for internal programs and to service the broader drug discovery industry was central to the Institute’s vision to achieve a long-term engagement with industry at a service level. In 2017, the Institute, with partners Fraunhofer ITEM and the Hannover Medical School in Germany, announced a major new multi million-dollar initiative, the International Consortium for Anti-Infectives Research (iCAIR).| Institute for Glycomics8

Commercialisation Case Study 1

Glycomics partnership with Olymvax

A partnership between Griffith and Olymvax Biopharmaceuticals will develop and test a vaccine against Group A streptococcal throat infections. If the trials prove successful, people could obtain lifetime protection from strep throat—and a host of more serious complications—from a single dose inhaled through the nose. While both the throat and skin infections are painful and debilitating, clinicians are far more worried about the dangerous conditions they can trigger if left untreated, including toxic shock syndrome, deep tissue infections and rheumatic heart disease, which collectively kill between 500,000 and a million people a year.

Commercialisation Case study 2

Early human patient trials: Ross River

Research conducted by Griffith University and Melbourne-based company Paradigm Biopharmaceuticals Limited (ASX: PAR) has uncovered a potential new therapeutic treatment in the global battle against mosquito-borne alphavirus infections, including the debilitating Ross River Virus (RRV) and Chikungunya Virus (CHIKV).

Currently RRV and CHIKV sufferers are only offered symptomatic management in the form of either non-steroidal anti-inflammatories or corticosteroids, which in some cases may actually exacerbate the condition.

These therapeutics may offer some short-term symptomatic relief but their use often results in detrimental side-effects while failing to treat the underlying disease. Researchers at Griffith University may have discovered a breakthrough in the treatment of mosquito-transmitted viral diseases like RRV and CHIKV.

Pre-clinical experiments conducted by researchers at Griffith University’s Institute for Glycomics on the Gold Coast have demonstrated world-first results showing that the historic drug, pentosan polysulfate sodium (PPS), can successfully treat both the acute and chronic disease manifestations symptoms of alphavirus infections in the animal model.


Professor Mark von Itzstein

One of the 2017, von Itzstein research group highlights was the discovery of a potent novel influenza virus neuraminidase inhibitor based on the carbohydrate, N-acetylneuraminic acid (Org Biomol Chem. 2017 15(25):5249-5253. doi: 10.1039/c7ob00947j). This compound, a sialosyl sulfonate, is efficiently prepared in only four steps from the parent carbohydrate N-acetylneuraminic acid and is not only a potent inhibitor of the virus’ neuraminidase, but also of influenza virus replication itself. Moreover, it provides an exciting opportunity for the development of next generation anti-influenza drugs that will be exploited during 2018. Finally, in collaboration with an industry partner Sirtex and ANU researchers, our group has discovered a small molecule anti-sepsis drug candidate that is presently in human clinical trials.

Our Remarkable research group highlights

Professor Michael Good

Streptococcal highlights for the last 12 months include the commencement of Stage II of the major collaborative research project with Olymvax to produce an intranasal streptococcal vaccine to prevent mucosal disease (with significant input from Drs. Mehfuz Zaman, Sharareh Eskandari and Michael Batzloff) and agreement from the Li Ka Shing Institute to fund a major trial of a vaccine to prevent skin and invasive disease in Canada (with major input from Dr. Pandey and the team in Alberta led by Drs. Mike Houghten and Lorne Tyrrell. NFMRI, the Snow Foundation and the Lowitja Institute have also provided significant funding support. With support from the END RHD CRE, Dr. Simone Reynolds has joined the lab to pursue vaccine and basic research questions in streptococcal biology, including a major collaborative project with Vaxxas to test a needle-less patch to deliver the J8-DT streptococcal vaccine. Other streptococcal highlights include the development of active and passive vaccines to prevent and treat streptococcal toxic shock syndrome, a collaboration involving Dr. Jenny Robson from Sullivan and Nicolaides.

Dr. Danielle Stanisic is now the Team Leader for Malaria within the lab. Major highlights for malaria include the continued and growing support from Rotary to fund the clinical component of a 3-dose escalation study of the chemically attenuated malaria vaccine, PlasProtecT, which will be followed by an infectious challenge. We have also received significant funding from NFMRI for vaccine manufacture in our GMP compliant facility. Major studies are now being written up describing the initial pilot immunogenicity studies of the vaccine in healthy volunteers and other pre-clinical studies looking at liposomal vaccine candidates and the development of a strategy to model the acquisition of naturally acquired malaria immunity using ‘delayed-death’ anti-malaria drugs. We are currently investigating PD-1 blocking peptides as a means to augment the responses induced by malaria vaccine candidates (in collaboration with Leidos). Alongside malaria, we are also working on vaccine strategies for Babesia, including chemical attenuation and liposomal preparations. This work involves a close collaboration with Dr. Sanjai Kumar, (US FDA).

Professor Michael Jennings

The Jennings Group made several contributions to understanding how bacteria utilise carbohydrate interactions to cause disease. These studies included work on the M protein of Group A streptococcus and its interaction with human blood group antigens (MBio. 2017; doi: 10.1128/mBio.02237-16), and a study on Streptococcus pneumoniae major adhesin PilA and the range of carbohydrates that it can bind to colonise humans (Scientific Reports. 2017 doi: 10.1038/s41598-017-17850-9). The lectins that bacterial produce to cause disease in humans such as toxins and adhesins can also be harnessed as biotechnology tools for use in other fields. In a study published in Scientific Reports (2017, doi: 10.1038/s41598-017-01522-9) we describe the Structure aided design of a Neu5Gc specific lectin based on the SubB toxin of the food bourn pathogen Escherichia coli. This new lectin has utility in detecting carbohydrate antigens made by cancer cells. The engineered SubB lectin has been patented and we are working with partners to develop this technology as a diagnostic tool for cancer.


Professor Suresh Mahalingam

We have made significantly progress towards the identification of new therapeutic targets for arbovirus-induced inflammation and tissue damage, and translate the findings into clinical use. In the past 2 years my group filed 2 patents and licensed 3 products. Patent 1, a drug t argetin g inflammation in alphavirus infection; licensed toParadigm Biopharma. A phase 2a clinical trial on RRV, funded by Paradigm, is underway inAustralia. A further clinical trial for CHIKV is planned for 2018 in Central America. Patent 2, a chikungunya vaccine; licensingnegotiations underway with a major international pharma. Provisional patent to be filed on a Zika vaccine and to be licensed to a major international pharma. Dengue antivirals licensed Biotron Ltd.

Professor Helen Blanchard

Professor Blanchard’s cancer research (funded by the Cancer Council Queensland) is focused on structure-based drug design targeting the cancer promoting proteins galectins. These proteins utilise carbohydrate-recognition in their biological and also disease progressing roles, and the compounds are designed to block the carbohydrate-recognition site with the aim of preventing protein function and thus reducing cancer progression. Professor Blanchard’s research into rotavirus is funded by the NHMRC.

As Principal Supervisor, Professor Blanchard successfully graduated one doctorate in 2017, with another person submitting their PhD thesis in January 2018. Helen is Principal Supervisor to 5 current HDR candidates and in 2017 she was awarded Griffith Sciences Pro Vice Chancellor’s Award in Research Excellence: Excellence in Research Supervision. Research undertaken on the rotavirus project during 2017 has been accepted in the Journal of Molecular Recognition, and that on galectin research is currently under review by Chemical biology and Drug Design, and by ChemMedChem. In galectin research, novel compounds have been designed, synthesised and the first atomic details of their interactions revealed with galectins involved in cancer including in bone cancers.

Professor Sue Berners- Price

The focus of research in the Berners-Price group has been to continue to develop projects under the new research theme of Metalloglycomics. Research funded by an ARC Discovery grant (a collaboration with Professor Nicholas Farrell, Virginia Commonwealth University, USA) develops our proof-of-concept (Chem. Commun., 2014, 50, 4056) that the strong binding of polynuclear platinum compounds (PPCs) to sulfated-oligosaccharides provides a new approach to glycan-based targeting, based on disruption of the heparan sulfate (HS)/heparanase (HPSE) interaction, through metalloshielding of critical sulfate residues involved in recognition. Highlights for 2017 include the publication of a comprehensive invited chapter on “Metalloglycomics” in Vol. 18 of Metal Ions in Life Sciences and a study published in Chemical Science (8, 241, 2017) that demonstrates that heparan sulfate is a ligand receptor for PPCs through sulfate cluster binding. Keynote and invited lectures were presented by Professor Sue Berners-Price and Research Fellow Dr Anil Kumar Gorle at at the 18th International Conference on Biological Inorganic Chemistry (Brazil July 2017) and the International Conference on Platinum Coordination Compounds in Cancer Chemotherapy (Sydney, Dec 2017).

Associate Professor Daniel Kolarich

After relocating to the Institute for Glycomics at Griffith University in early 2017 we have been focussing on establishing the new Advanced Mass Spectrometry Facility, which is also part of the Australian Centre for Cancer Glycomics (A2CG). After more than 12 months of planning and construction we finally could start to move into the purpose build laboratories and use these now installed capabilities to start uncovering the secrets hidden in cancer glycosylation. We also published a number of articles. Together with researchers from the Swiss Institute for Bioinformatics we have been working on a novel tool supporting glycopeptide mass spectra annotation, published in the journal Proteomics Clinical


Applications. Stepping into the field of bacterial glycomics/glycoproteomics in collaboration with scientists from the University of Natural Resources and Applied Life Sciences in Vienna, Austria, we uncovered for the first time the flagellin O-glycan structures of the periodontitis associated pathogen Selenomonas sputigena, revealing hitherto never before described O-glycans that in future could be potential vaccine targets. These specific O-glycans also allowed us to systematically investigate glycopeptide specific fragmentation patterns that can help to improve automated data analyses in the future. Most importantly, in our work recently published in “Frontiers in Oncology” we undertook the first detailed investigation of the normal human skin glycome and glycoproteome and uncovered the changes occurring during non-melanoma type skin cancers, providing a better understanding on the molecular events occurring during cancer pathogenesis and the biosynthetic machinery responsible to glycosylate glycoproteins. This has been an important step forward in our quest to systematically target the cancer glycome as a source for novel diagnostic, prognostic and therapeutic markers.

Associate Professor Thomas Haselhorst

My group has been actively engaged in elucidating the structure of Glycan-Glycan interactions by NMR spectroscopy in collaboration with Prof. Michael Jennings within the framework of a joint ARC grant. Postdoctoral researcher Dr Freda Jens has collected large NMR datasets under my supervision that are currently analysed and prepared for publication. My group has also been actively engaged in sourcing additional computing capacity and we are now able to use the QCIF (Queensland Cyber Infrastructure Foundation) HPC cluster for extensive Molecular Dynamics simulations and in-silico drug screening experiments. The latter approach has already resulted in some attractive drug leads for a number of attractive drug targets - in particular for a collaborative research project with the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM and Hannover Medical School (MHH). A student from the University of Bremen has applied for a Griffith University HDR scholarship to work on this collaborative project in 2018 for the evaluation of these identified drug leads.

Dr Darren Grice

(i) We have assembled a carbohydrate-based conjugate vaccine (carbohydrate from Moraxella catarrhalis, outer membrane protein from non-typeable Haemophilus influenzae) to potentially protect against acute Otitis media (middle ear infection) and respiratory diseases. A mice challenge study with this conjugate vaccine has now been completed, with results indicating that the vaccine candidate presents an exciting basis for further ongoing development. A manuscript reporting aspects of the vaccine conjugate assembly and animal challenge results has been prepared, with submission planned for May 2018. The project has been funded by philanthropic support from the John Villier’s Trust.

(ii) Synthesis of a novel leukaemia therapeutic has been further progressed, with the final synthetic stage presently underway. Compound will be sent to collaborators in USA for studies directly upon completion.

(iii) Completed work on the synthesis of cancer therapeutics targeting Galectin-3 has been incorporated into several manuscripts. One manuscript submitted, the other nearing submission.

(iv) The first round of synthetic analogues of a potent antiviral isolated (by us) from a marine plant in the Ganges river Sundarbans (Bangladesh) has been completed. Samples have been passed to collaborators for antiviral assay. Results will guide our ongoing synthetic work.

Associate Professor Joe Tiralongo

In 2017 highlights from the Tiralongo group included the establishment of a significant collaboration with Integria Healthcare funded through commercial contract research, and seed funding from both Griffith University and Integria Healthcare. In addition, work commenced on an Industry-based ARC Linkage funded project in collaboration with BioDiem Pty. An additional grant success in 2017 was the awarding of an ARC Linkage Infrastructure, Equipment and Facilities (LIEF) grant in collaboration with the University of QLD (Joe Tiralongo lead Griffith Investigator). Publication and invited lecture highlights include papers published in Scientific Reports, Proteins, and a student publication in Glycoconjugate Journal, as well as invited lectures at two international conferences in China and Taiwan.


Professor Yaoqi Zhou

Professor Zhou’s group made a significant progress in using modern deep learning techniques to predict structures from protein sequences. For the first time, employing long short-term memory bidirectional recurrent neural networks allows learning from the whole protein sequence rather from a segment of the protein sequence. Results were reported in several articles published in Bioinformatics (33: 677-684, 685—692, 2842-2849, 2017). A proposal based on these preliminary studies was awarded the ARC Discovery Project in collaboration with Prof Kuldip Paliwal (Protein structure prediction by deep long-range learning). Moreover, novel methods were developed for distinguishing disease-causing from neutral genetic variations with a significantly improved level of accuracy (Human Mutations, 38, 16-24, 2842-2849, 1336-1347, Human Genetics, 136: 1279–1289, 2017). In addition, an improved technique for high-throughput-screening of small molecules was developed by the binding homology approach (Bioinformatics, 33:1238—1240, 2017) and the first technique for predicting RNA solvent accessible surface area was established and applied to investigate thermal adaptation of bacterial coding and non-coding RNAs (RNA, 23: 14-22, 2017, PLOS one 12, e0184722, 2017). Furthermore, together with our collaborator in China we demonstrated that a multi-channel graphene biosensor can provide reliable, real-time determination of binding kinetics of DNA hybridization, opening the door for the miniature device for binding affinity measurement. A total of 15 peer-reviewed journal articles, 3 book chapters, and one communication were published in 2017.

Dr Todd Houston

This past year, the Houston group made significant advances in the development of novel methods to treat macrophage-resident infections (e.g.-tuberculosis, “golden staph”). We have identified a glycolipid that interacts with macrophages and reduces the cytokine production caused by LPS stimulation that normally causes sepsis. We have published an invited paper in the German journal Heterocyclic Communications describing a unique boron-promoted esterification. This work is being extended in our development of boron-based carbohydrate receptors. Importantly, we have received a significant grant in this area ($900K AUD) from Sugar Research Australia to apply our boron work to the improvement of sugar cane production.

Associate Professor Kate Seib

During 2017, Assoc. Prof Kate Seib’s group has been working on understanding the processes involved in host colonisation and disease, with the aim to identify therapeutic targets of bacterial pathogens including Neisseria gonorrhoeae (causes the sexually transmitted infection gonorrhoea, which can lead to infertility), Neisseria meningitidis (causes sepsis and meningitis) and Moraxella catarrhalis and non-typeable Haemophilus influenzae (causes middle ear infections and exacerbations of chronic obstructive pulmonary disease). Research highlights include the

characterisation of a novel vaccine target for N. gonorrhoeae (Semchenko et al., Infection and Immunity 2017) and an invited commentary on gonococcal vaccine advancements (Seib, Lancet, 2017). Dr Tsitsi Diana Mubaiwa was awarded her PhD and won the Institute for Glycomics’ Directors Medal for excellence in Higher Degree Research, and her significant research in deciphering the glycointeractome of Neisseria meningitidis and contributing to the field of knowledge relating to the meningococcal serogroup B vaccine (Mubaiwa et al, Scientific Reports, 2017). Mr Luke Blakeway (PhD candidate) was selected to participate in the CSHL 2017 Advanced Bacterial Genetics Course in New York.

Dr Milton Kiefel

In 2017 the Kiefel group continued their investigations into the synthesis of novel nonulosonic acids. These sugars are unique to Gram negative bacteria, and are known to be directly associated with the virulence of some of the most dangerous pathogenic bacteria known. Key highlights from the year include completing the synthesis of legionaminic acid (achieved by James Carter who is soon to submit his PhD thesis). When we publish this synthesis later in 2018, the Kiefel group will be the only research group in the world to have successfully developed unique synthetic methods to allow access to three key bacterial sugars, namely KDO (published in 2010), pseudaminic acid (published in 2016)


and now legionaminic acid. Other highlights from 2017 include a 3 month sabbatical by Dr Kiefel at the University of Canterbury (NZ) where he established a new collaboration with A/Prof Ren Dobson. This collaboration seeks to combine the synthetic chemistry skills of the Kiefel group with the mechanistic and structural expertise of the Dobson group in looking at bacterial proteins associated with virulence.

Professor Victoria Korolik

Korolik group is currently focused on studying the role of bacterial chemotaxis in pathogenicity and bacteria-host interactions, specifically, on deciphering ligand binding specificities of transmembrane chemosensory proteins of Campylobacter jejuni,Campylobacter fetus and Helicobacter pylori. Recent breakthroughs of the Korolik group are highlighted by the discovery of a novel class of bacterial chemosensors with broad ligand specificities that may be related to sensing of the host molecules, and thus, may play a role in host-bacterial interactions. The group is currently developing a new research area focused on biofilm formation and its role in disease transmission for campylobacters. The group has published five refereed papers in 2017 and Professor Victoria Korolik has delivered an invited symposium presentation at the Host-Pathogen meeting, INERM, France and the invited Plenary Lecture at the 2017 Campylobacter, Helicobacter and Related Organisms international meeting.

Professor Johnson Mak

Our discovery of a previous unknown ‘Pre-Entry Priming of HIV’ has been funded by NHMRC with a 4-year project grant. With NHMRC support, we will explore the potential of using this information to develop a novel HIV vaccine, and interrogate the mechanistic insights that underpin these processes, as well as define their implications on HIV and virology in general. In collaboration with Paul Hertzog at Hudson Institute, we have discovered a female reproductive tract specific cytokine, interferon epsilon, that has potent suppressive activity against HIV, pathing the way for development of an effective HIV prevention strategy that can be dictated by women. Building

from our pioneer effort in production of full-length recombinant HIV Gag protein to investigate HIV assembly and maturation, we have provided first evidence how HIV utilizes the thermodynamic properties of viral protein and RNA interaction to drive the biogenesis of infectious HIV. By taking advantage of our expertise in this area, we will define the biophysical properties of HIV assembly and maturation for the development of HIV maturation inhibitor for the clinic. Johnson Mak has been appointed as Co-Editor-in-Chief for Retrvoriology, a prestigious scientific journal in the field of HIV. Most important of all, the Mak lab is delighted to join Institute for Glycomics at Griffith University in 2017 and to work with Griffith staff (who are known to have strong translational experience) to further contribute to finding practical solutions for those who have been affected by HIV and AIDS.

Dr Lara Herrero

2017 was a productive year for the Herrero Group with a number of research outputs across different areas. Some of the highlights include:

• Dr Penny Rudd was successful in winning an Advance QLD Government Fellowship for our Ross River virus pentosan clinical trial (total value $1.2 million).

• The Phase II clinical trial run funded by Paradigm Biopharma (based on the research from the Herrero group) commenced with recruitment sites including the Griffith Clinical trials unit on the Gold Coast.

• Dr Herrero served on as a peer reviewer for the ARC discovery grants and on the GRP for NHMRC

• Dr Herrero was an invited or selected speaker for a number of national and international conferences including- Session Chair (Dec 2017) AVS, SA, Aus. Invited Speaker (July 2017) IUMS, Singapore.Session Chair (July 2017) IUMS, Singapore. Selected Speaker (June 2017) ASV, Wisconsin, MI, USA.

• Dr Herrero was a Finalist Women in Technology Research Leader award (one of three finalists), and won the Griffith University’s Glycomics Mid Career Researcher award.

• The group (with collaborators) published 6 peer-reviewed journal articles plus one book chapter.

• Dr Herrero was a frequent guest speaker on local and national radio discussing the recent surge in RRV

• The lab expanded and now has 6 PhD students and two post docs.


FacilitiesOur state-of-the art amenities facilitate our world-class researchOur range of facilities covers the entire spectrum of drug discovery and development, including:

• Separation science

• Glycobioanalytical facility

• Computational chemistry and visualisation

• Nuclear magnetic resonance and spectroscopy

• Protein X-ray crystallography

• Flow cytometry and cell sorting

• Cell and animal irradiation

• Zyme Bank

• Mass Spectrometry.

New in 2017

Mass Spectrometry

A multi-million dollar investment by Griffith University allowed the establishment of a new glycomics and glycoproteomics focussed Advanced Mass Spectrometry Laboratory, embedded at the Institute for Glycomics.

As part of the Australian Centre for Cancer Glycomics (A2CG) a major focus of this Mass Spectrometry laboratory is to push the boundaries in biomedical research and working towards the discovery of new cancer diagnostics, drugs and vaccines, which will have global impact. This purpose build laboratory currently hosts three state-of-the-art high-end mass spectrometers catering for different challenges in cancer and disease glycomics.

We are using these modern technologies to understand and translate the glycome changes occurring in cancer to identify new therapeutic targets, develop novel diagnostics for precision medicine and gain a better general understanding of cancer biology.


To achieve these aims, we are using an

1.) Orbitrap™ Fusion™ mass spectrometer that is coupled to a nano-liquid chromatography system, enabling us to perform multi-dimensional separation, detection and fragmentation of biomolecules.

2.) rapifle™ tissue imager to visualise and identify diagnostic markers in tissue sections and understand their distribution in cancer tissues

3.) amaZon speed ion trap mass spectrometer coupled to a nano-liquid chromatography system providing us with the opportunity to perform clinical glycomics with the highest sensitivity and selectivity.

We are also offering one-stop services and solutions for industrial glycomics and glycoproteomics challenges and questions, with the team having over 60 combined years of experience in analytical glycobiology, glycomics and glycoproteomics.

ZymeBank

Recently established within the Institute for Glycomics, the Zymebank facility provides enzymes that support both internal and external research projects. By cloning into various mammalian or bacterial expression vectors, Zymebank is able to produce enzymes essential for glycan synthesis in high quality and purity. Activity assays have been developed to allow for in-depth characterisation of enzyme functions which guides enzyme use in downstream applications such as chemo-enzymatic synthesis. Currently, a range of human and bacterial sialyltransferases and fucosyltransferases have been expressed and characterised. Enzymes for sugar-nucleotide biosynthesis and nucleotide triphosphate regeneration are also available. We currently have nearly 30 enzymes in stock, and this number is growing rapidly. Zymebank also provides technical support in molecular cloning, expression, purification, and assay development.

Zymebank offers:

1. ready to use enzymes

2. expression plasmids (in-house cloned)

3. molecular cloning

4. protein expression and purification

5. assay development.

We are using these modern technologies to understand and translate the glycome changes occurring in cancer to identify new therapeutic targets


2017 Glycomics publications

1. Abrahams, JL, Campbell, MP, and Packer, NH. (2017). Building a PGC-LC-MS N-glycan retention library and elution mapping resource, Glycoconj J: doi: 10.1007/s10719-10017-19793-10714.

2. Anugraham, M, Jacob, F, Everest-Dass, AV, Schoetzau, A, Nixdorf, S, Hacker, NF, Fink, D, Heinzelmann-Schwarz, V, and Packer, NH. (2017). Tissue glycomics distinguish tumour sites in women with advanced serous adenocarcinoma, Mol Oncol 11 (11): 1595-1615.

3. Blakeway, LV, Tan, A, Peak, IRA, and Seib, KL. (2017). Virulence determinants of Moraxella catarrhalis: distribution and considerations for vaccine development, Microbiology-Sgm 163 (10): 1371-1384.

4. Brockman, KL, Branstool, MT, Atack, JM, Robledo-Avila, F, Partida-Sanchez, S, Jennings, MP, and Bakaletz, LO. (2017). The ModA2 Phasevarion of nontypeable Haemophilus influenzae Regulates Resistance to Oxidative Stress and Killing by Human Neutrophils, Sci Rep 7: a3161.

5. Brown, P, and Zhou, Y. (2017). Biomedical literature: Testers wanted for article search tool, Nature 549 (7670): 31.

6. Bunn, PT, de Oca, MM, Rivera, FD, Kumar, R, Edwards, CL, Faleiro, RJ, Ng, SS, Sheel, M, Wang, YL, Amante, FH, Haque, A, and Engwerda, CR. (2017). Galectin-1 Impairs the Generation of Anti-Parasitic Th1 Cell Responses in the Liver during Experimental Visceral Leishmaniasis, Front Immunol 8: a1307.

7. Burt, FJ, Chen, WQ, Miner, JJ, Lenschow, DJ, Merits, A, Schnettler, E, Kohl, A, Rudd, PA, Taylor, A, Herrero, LJ, Zaid, A, Ng, LFP, and Mahalingam, S. (2017). Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen, Lancet Infect Dis 17 (4): E107-E117.

8. Calderon-Gomez, LI, Day, CJ, Hartley-Tassell, LE, Wilson, JC, Mendz, GL, and Korolik, V. (2017). Identification of NuoX and NuoY Ligand Binding Specificity in the Campylobacter Jejuni Complex I, J Bacteriol Parasitol 8 (2): DOI: 10.4172/2155-9597.1000307.

9. Campbell, M. (2017). A review of software applications and databases for the interpretation of glycopeptide data, TIGG 29(168): E51-E62.

10. Campbell, MP, Aoki-Kinoshita, KF, Lisacek, F, York, WS, and Packer, NH. (2017) Glycoinformatics, In Essentials of Glycobiology 3rd Ed (Varki, A, Cummings, RD, Esko, JD, Stanley, P, Hart, GW, Aebi, M, Darvill, AG, Kinoshita, T, Packer, NH, Prestegard, JH, Schnaar, RL, and Seeberger, PH, Eds.), Cold Spring Harbor Laboratory Press.

11. Cao, HS, Wei, D, Yang, YD, Shang, Y, Li, GY, Zhou, YQ, Ma, Q, and Xu, Y. (2017). Systems-level understanding of ethanol-induced stresses and adaptation in E. coli, Sci Rep 7: a44150.

12. Carraro, M, Minervini, G, Giollo, M, Bromberg, Y, Capriotti, E, Casadio, R, Dunbrack, R, Elefanti, L, Fariselli, P, Ferrari, C, Gough, J, Katsonis, P, Leonardi, E, Lichtarge, O, Menin, C, Martelli, PL, Niroula, A, Pal, LR, Repo, S, Scaini, MC, Vihinen, M, Wei, Q, Xu, QF, Yang, YD, Yin, YZ, Zaucha, J, Zhao, HY, Zhou, YQ, Brenner, SE, Moult, J, and Tosatto, SCE. (2017). Performance of in silico tools for the evaluation of p16INK4a (CDKN2A) variants in CAGI, Hum Mutat 38 (9): 1042-1050.

13. Cates, JE, Unger, HW, Briand, V, Fievet, N, Valea, I, Tinto, H, D’Alessandro, U, Landis, SH, Adu-Afarwuah, S, Dewey, KG, Ter Kuile, FO, Desai, M, Dellicour, S, Ouma, P, Gutman, J, Oneko, M, Slutsker, L, Terlouw, DJ, Kariuki, S, Ayisi, J, Madanitsa, M, Mwapasa, V, Ashorn, P, Maleta, K, Mueller, I, Stanisic, D, Schmiegelow, C, Lusingu, JPA, van Eijk, AM, Bauserman, M, Adair, L, Cole, SR, Westreich, D, Meshnick, S, and Rogerson, S. (2017). Malaria, malnutrition, and birthweight: A meta-analysis using individual participant data, PLoS Med 14 (8): e1002373.

14. Chan, JA, Stanisic, DI, Duffy, MF, Robinson, LJ, Lin, E, Kazura, JW, King, CL, Siba, PM, Fowkes, FJI, Mueller, I, and Beeson, JG. (2017). Patterns of protective associations for antibodies to surface antigens of P. falciparum-infected erythrocytes and merozoites among children suggest different roles in malaria immunity, Eur J Immunol 47 (12): 2124-2136.

15. Chen, S, Yang, C, Mahalingam, S, Wang, M, and Cheng, A. (2017). An updated review of avian-origin Tembusu virus: a newly emerging avian Flavivirus, J Gen Virol 98 (10): 2413-2420.

16. Chen, WQ, Foo, SS, Zaid, A, Teng, TS, Herrero, LJ, Wolf, S, Tharmarajah, K, Vu, LD, van Vreden, C, Taylor, A, Freitas, JR, Li, RW, Woodruff, TM, Gordon, R, Ojcius, DM, Nakaya, HI, Kanneganti, TD, O’Neill, LAJ, Robertson, AAB, King, NJ, Suhrbier, A, Cooper, MA, Ng, LFP, and Mahalingam, S. (2017). Specific inhibition of NLRP3 in chikungunya disease reveals a role for inflammasomes in alphavirus-induced inflammation, Nat Microbiol 2 (10): 1435-1445.

17. Choo, M, Tan, HL, Ding, V, Castangia, R, Belgacem, O, Liau, B, Hartley-Tassell, L, Haslam, SM, Dell, A, and Choo, A. (2017). Characterization of H type 1 and type 1 N-acetyllactosamine glycan epitopes on ovarian cancer specifically recognized by the anti-glycan monoclonal antibody mAb-A4, J Biol Chem 292 (15): 6163-6176.


18. Day, CJ, Hartley-Tassell, LE, and Korolik, V. (2017) Identification of Ligand-Receptor Interactions: Ligand Molecular Arrays, SPR and NMR Methodologies, In Campylobacter Jejuni: Methods and Protocols (Butcher, J, and Stintzi, A, Eds.), pp 51-63.

19. Day, C, Paton, AW, Harvey, RM, Hartley-Tassell, LE, Seib, KL, Tiralongo, J, Bovin, N, Savino, S, Masignani, V, Paton, JC, and Jennings, MP. (2017). Lectin activity of the pneumococcal pilin proteins, Sci Rep 7: a17784.

20. Day, CJ, Paton, AW, Higgins, MA, Shewell, LK, Jen, FEC, Schulz, BL, Herdman, BP, Paton, JC, and Jennings, MP. (2017). Structure aided design of a Neu5Gc specific lectin, Sci Rep 7: a1495.

21. De Oliveira, DMP, Hartley-Tassell, L, Everest-Dass, A, Day, CJ, Dabbs, RA, Ve, T, Kobe, B, Nizet, V, Packer, NH, Walker, MJ, Jennings, MP, and Sanderson-Smith, ML. (2017). Blood Group Antigen Recognition via the Group A Streptococcal M Protein Mediates Host Colonization, Mbio 8 (1).

22. Dirr, L, El-Deeb, IM, Chavas, LMG, Guillon, P, and von Itzstein, M. (2017). The impact of the butterfly effect on human parainfluenza virus haemagglutinin-neuraminidase inhibitor design, Sci Rep 7: a4507.

23. Domagalski, MJ, Alocci, D, Almeida, A, Kolarich, D, and Lisacek, F. (2017). PepSweetener: A Web-Based Tool to Support Manual Annotation of Intact Glycopeptide MS Spectra, Proteomics Clin Appl: doi: 10.1002/prca.201700069.

24. Du Toit, E, Browne, L, Irving-Rodgers, H, Massa, HM, Fozzard, N, Jennings, MP, and Peak, IR. (2017). Effect of GPR84 deletion on development of obesity and diabetes in mice fed long chain or medium chain fatty rich diets, Eur J Nutr: doi: 10.1007/s00394-00017-01456-00395.

25. Elgamoudi, BA, and Ketley, JM. (2017). Lighting up my life: a LOV-based fluorescent reporter for Campylobacter jejuni, Res Microbiol: doi: 10.1016/j.resmic.2017.1010.1003.

26. Fagan, V, Hussein, WM, Su, M, Giddam, AK, Batzloff, MR, Good, MF, Toth, I, and Simerska, P. (2017). Synthesis, Characterization and Immunological Evaluation of Self-Adjuvanting GroupA Streptococcal Vaccine Candidates Bearing Various Lipidic Adjuvanting Moieties, Chembiochem 18 (6): 545-553.

27. Faraggi, E, Kouza, M, Zhou, Y, and Kloczkowski, A. (2017) Fast and Accurate Accessible Surface Area Prediction Without a Sequence Profile, In Prediction of Protein Secondary Structure (Zhou, Y, Kloczkowski, A, Faraggi, E, and Yang, Y, Eds.), pp 127-136, Humana Press.

28. Floch, P, Capdevielle, C, Staedel, C, Izotte, J, Sifre, E, Laur, AM, Giese, A, Korolik, V, Dubus, P, Megraud, F, and Lehours, P. (2017). Deregulation of MicroRNAs in Gastric Lymphomagenesis Induced in the d3Tx Mouse Model of Helicobacter pylori Infection, Front Cell Infect Microbiol 7: a185.

29. Floch, P, Izotte, J, Guillemaud, J, Sifre, E, Costet, P, Rousseau, B, Laur, AM, Giese, A, Korolik, V, Megraud, F, Dubus, P, Hahne, M, and Lehours, P. (2017). A New Animal Model of Gastric Lymphomagenesis APRIL Transgenic Mice Infected by Helicobacter Species, Am J Pathol 187 (7): 1473-1484.

30. Ghadimi, M, Blums, V, Norton, BG, Fisher, PM, Connell, SC, Amini, JM, Volin, C, Hayden, H, Pai, CS, Kielpinski, D, Lobino, M, and Streed, EW. (2017). Scalable ion-photon quantum interface based on integrated diffractive mirrors, Npj Quantum Inf 3: a4.

31. Good, MF, and Yanow, SK. (2017). A whole parasite transmission-blocking vaccine for malaria: an ignored strategy, Emerg Top Life Sci 1 (6): 547-552.

32. Guruge, I, Taherzadeh, G, Zhan, J, Zhou, Y, and Yang, Y. (2017). B-factor profile prediction for RNA flexibility using support vector machines, J Comput Chem 39 (8): 407-411.

33. Hadhazi, A, Pascolutti, M, Bailly, B, Dyason, JC, Borbas, A, Thomson, RJ, and von Itzstein, M. (2017). A sialosyl sulfonate as a potent inhibitor of influenza virus replication, Org Biomol Chem 15 (25): 5249-5253.

34. Heffernan, R, Yang, YD, Paliwal, K, and Zhou, YQ. (2017). Capturing non-local interactions by long short-term memory bidirectional recurrent neural networks for improving prediction of protein secondary structure, backbone angles, contact numbers and solvent accessibility, Bioinformatics 33 (18): 2842-2849.

35. Herrero, LJ, Zaid, A, Mutso, M, and Mahalingam, S. (2017) The MIF-CD74 Axis in Alphaviral Infection, In MIF Family Cytokines in Innate Immunity and Homeostasis. Progress in Inflammation Research (Bucala, R, and Bernhagen, J, Eds.), pp 175-187, Springer, Cham.

36. Hinneburg, H, Korac, P, Schirmeister, F, Gasparov, S, Seeberger, PH, Zoldos, V, and Kolarich, D. (2017). Unlocking Cancer Glycomes from Histopathological Formalin-fixed and Paraffin-embedded (FFPE) Tissue Microdissections, Mol Cell Proteomics 16 (4): 524-536.

37. Houston, TA. (2017). A simple visual demonstration of membrane permeability, The Chemist 90 (2): 23-24.

38. Hueston, L, Ramirez, R, and Mahalingam, S. (2017). Enhancement of Zika Infection by Dengue Virus-Specific Antibody Is Associated With Low Levels of Antiviral Factors, J Infect Dis 216 (5): 612-614.


39. Hughes, MM, Lavrencic, P, Coll, RC, Ve, T, Ryan, DG, Williams, NC, Menon, D, Mansell, A, Board, PG, Mobli, M, Kobe, B, and O’Neill, LAJ. (2017). Solution structure of the TLR adaptor MAL/TIRAP reveals an intact BB loop and supports MAL Cys91 glutathionylation for signaling, Proc Natl Acad Sci U S A 114 (32): E6480-E6489.

40. Hussein, WM, Mukaida, S, Azmi, F, Bartlett, S, Olivier, C, Batzloff, MR, Good, MF, Slovarczynski, M, and Toth, I. (2017). Comparison of Fluorinated and Nonfluorinated Lipids in Self-Adjuvanting Delivery Systems for Peptide-Based Vaccines, Med Chem Lett 8 (2): 227-232.

41. Jacobs, SC, Taylor, A, Herrero, LJ, Mahalingam, S, and Fazakerley, JK. (2017). Mutation of a Conserved Nuclear Export Sequence in Chikungunya Virus Capsid Protein Disrupts Host Cell Nuclear Import, Viruses Basel 9 (10): a306.

42. Jegousse, C, Yang, YD, Zhan, J, Wang, JH, and Zhou, YQ. (2017). Structural signatures of thermal adaptation of bacterial ribosomal RNA, transfer RNA, and messenger RNA, PLoS One 12 (9): e0184722.

43. Kan-o, K, Ramirez, R, MacDonald, MI, Rolph, M, Rudd, PA, Spann, KM, Mahalingam, S, Bardin, PG, and Thomas, BJ. (2017). Human Metapneumovirus Infection in Chronic Obstructive Pulmonary Disease: Impact of Glucocorticosteroids and Interferon, J Infect Dis 215 (10): 1536-1545.

44. King, NJC, Teixeira, MM, and Mahalingam, S. (2017). Zika Virus: Mechanisms of Infection During Pregnancy, Trends Microbiol 25 (9): 701-702.

45. King, RM, and Korolik, V. (2017) Characterization of Ligand-Receptor Interactions: Chemotaxis, Biofilm, Cell Culture Assays, and Animal Model Methodologies, In Campylobacter Jejuni: Methods and Protocols (Butcher, J, and Stintzi, A, Eds.), pp 149-161, Humana Press, New York.

46. Langshaw, EL, Pandey, M, and Good, MF. (2018). Cellular interactions of covR/S mutant group A streptococci. Microbes and Infections, Microbes Infect: doi.org/10.1016/j.micinf.2017.1012.1009. (Epub date 26 Dec 2017)

47. Lee, WS, Supramaniam, A, Lim, EXY, Coles, P, and Herrero, LJ. (2017). Alphaviral targeted antivirals: evaluating the old, planning the future, Future Virol 12 (2): 49-54.

48. Lin, C-H, Krisp, C, Packer, NH, and Molloy, MP. (2018). Development of a data independent acquisition mass spectrometry workflow to enable glycopeptide analysis without predefined glycan compositional knowledge, J Proteomics 172: 68-75. (Epub date 22 Oct 2017)

49. Litfin, T, Zhou, YQ, and Yang, YD. (2017). SPOT- ligand 2: improving structure-based virtual screening by binding-homology search on an expanded structural template library, Bioinformatics 33 (8): 1238-1240.

50. Liu, X, Tharmarajah, K, and Taylor, A. (2017). Ross River virus disease clinical presentation, pathogenesis and current therapeutic strategies, Microbes Infect 19 (11): 496-504.

51. Livingstone, M, Folkman, L, Yang, YD, Zhang, P, Mort, M, Cooper, DN, Liu, YL, Stantic, B, and Zhou, YQ. (2017). Investigating DNA-, RNA-, and protein-based features as a means to discriminate pathogenic synonymous variants, Hum Mutat 38 (10): 1336-1347.

52. Loughland, JR, Minigo, G, Sarovich, DS, Field, M, Tipping, PE, de Oca, MM, Piera, KA, Amante, FH, Barber, BE, Grigg, MJ, William, T, Good, MF, Doolan, DL, Engwerda, CR, Anstey, NM, McCarthy, JS, and Woodberry, T. (2017). Plasmacytoid dendritic cells appear inactive during sub-microscopic Plasmodium falciparum blood-stage infection, yet retain their ability to respond to TLR stimulation, Sci Rep 7: a2596.

53. Low, LM, Stanisic, DI, and Good, MF. (2018). Exploiting the apicoplast: apicoplast-targeting drugs and malaria vaccine development, Microbes Infect: doi.org/10.1016/j.micinf.2017.1012.1005. (Epub date 26 Dec 2017)

54. Mahalingam, S, Teixeira, MM, and Halstead, SB. (2017). Zika enhancement: a reality check, Lancet Infect Dis 17 (7): 686-688.

55. Mahdi, LK, Higgins, MA, Day, CJ, Tiralongo, J, Hartley-Tassell, LE, Jennings, MP, Gordon, DL, Paton, AW, Paton, JC, and Ogunniyi, AD. (2017). The Pneumococcal Alpha-Glycerophosphate Oxidase Enhances Nasopharyngeal Colonization through Binding to Host Glycoconjugates, Ebiomedicine 18: 236-243.

56. Mallard, BW, and Tiralongo, J. (2017). Cancer stem cell marker glycosylation: Nature, function and significance, Glycoconj J 34 (4): 441-452.

57. McLean, ARD, Stanisic, D, McGready, R, Chotivanich, K, Clapham, C, Baiwog, F, Pimanpanarak, M, Siba, P, Mueller, I, King, CL, Nosten, F, Beeson, JG, Rogerson, S, Simpson, JA, and Fowkes, FJI. (2017). P. falciparum infection and maternofetal antibody transfer in malaria-endemic settings of varying transmission, PLoS One 12 (10): e0186577.

58. Md Foisal, AR, Qamar, A, Phan, HP, Dinh, T, Tuan, KN, Tanner, P, Streed, EW, and Dao, DV. (2017). Pushing the limits of piezoresistive effect by opto-mechanical coupling in 3C-SiC/Si heterostructure, ACS Appl Mater Interfaces 9 (46): 39921-39925.


59. Mubaiwa, TD, Hartley-Tassell, LE, Semchenko, EA, Jen, FEC, Srikhanta, YN, Day, CJ, Jennings, MP, and Seib, KL. (2017). The glycointeractome of serogroup B Neisseria meningitidis strain MC58, Sci Rep 7: a5693.

60. Mubaiwa, TD, Semchenko, EA, Hartley-Tassell, LE, Day, CJ, Jennings, MP, and Seib, KL. (2017). The sweet side of the pathogenic Neisseria: the role of glycan interactions in colonisation and disease, Pathog Dis 75 (5): ftx063.

61. Mutso, M, Saul, S, Rausalu, K, Susova, O, Zusinaite, E, Mahalingam, S, and Merits, A. (2017). Reverse genetic system, genetically stable reporter viruses and packaged subgenomic replicon based on a Brazilian Zika virus isolate, J Gen Virol 98 (11): 2712-2724.

62. Nimma, S, Ve, T, Williams, SJ, and Kobe, B. (2017). Towards the structure of the TIR-domain signalosome, Curr Opin Struct Biol 43: 122-130.

63. Nordstrom, T, Pandey, M, Calcutt, A, Powell, J, Phillips, ZN, Yeung, G, Giddam, AK, Shi, Y, Haselhorst, T, von Itzstein, M, Batzloff, MR, and Good, MF. (2017). Enhancing Vaccine Efficacy by Engineering a Complex Synthetic Peptide To Become a Super Immunogen, J Immunol 199 (8): 2794-2802.

64. O’Neill, EC, Kuhaudomlarp, S, Rejzek, M, Fangel, JU, Alagesan, K, Kolarich, D, Willats, WGT, and Field, RA. (2018). Exploring the Glycans of Euglena gracilis, Biology (Basel) 6 (4): E45.

65. Pandey, M, Powell, J, Calcutt, A, Zaman, M, Phillips, ZN, Ho, MF, Batzloff, MR, and Good, MF. (2017). Physicochemical characterisation, immunogenicity and protective efficacy of a lead streptococcal vaccine: progress towards Phase I trial, Sci Rep 7(1): 13786.

66. Pappin, BB, Levonis, SM, Healy, PC, Kiefel, MJ, Simone, MI, and Houston, TA. (2017). Crystallization-induced amide bond formation creates a boron-centered spirocyclic system, Heterocycl Commun 23 (3): 167-169.

67. Prakasha, A, Grice, ID, Kumar, KSV, Sadashiva, MP, Shankar, HN, and Umesha, S. (2017). Extracellular polysaccharide from Ralstonia solanacearum; A strong inducer of eggplant defense against bacterial wilt, Biol Control 110: 107-116.

68. Raja, A, Stanisic, DI, and Good, MF. (2017) Immune responses to whole organism blood-stage malaria vaccines, In Malaria: immune response to infection and vaccination (Rodriguez, A, and Mota, MM, Eds.), pp 197-210, Springer.

69. Raja, AI, Stanisic, DI, and Good, MF. (2017). Chemical Attenuation in the Development of a Whole-Organism Malaria Vaccine, Infect Immun 85 (7): e00062-00017.

70. Ribeiro, JP, Hassan, MAA, Rouf, R, Tiralongo, E, May, TW, Day, CJ, Imberty, A, Tiralongo, J, and Varrot, A. (2017). Biophysical characterization and structural determination of the potent cytotoxic Psathyrella asperospora lectin, Proteins-Struc Funct Bioinf 85 (5): 969-975.

71. Rouquette-Loughlin, CE, Zalucki, YM, Dhulipala, VL, Balthazar, JT, Doyle, RG, Nicholas, RA, Begum, AA, Raterman, EL, Jerse, AE, and Shafer, WM. (2017). Control of gdhR Expression in Neisseria gonorrhoeae via Autoregulation and a Master Repressor (MtrR) of a Drug Efflux Pump Operon, Mbio 8 (2): e00449-00417.

72. Rudd, P, Karlsson, NG, Khoo, KH, and Packer, NH. (2017) Glycomics and Glycoproteomics, In Essentials of Glycobiology 3rd Ed (Varki, A, Cummings, RD, Esko, JD, Stanley, P, Hart, GW, Aebi, M, Darvill, AG, Kinoshita, T, Packer, NH, Prestegard, JH, Schnaar, RL, and Seeberger, PH, Eds.), Cold Spring Harbor Laboratory Press.

73. Rudd, PA, Thomas, BJ, Zaid, A, MacDonald, M, Kan-O, K, Rolph, MS, Soorneedi, AR, Bardin, PG, and Mahalingam, S. (2017). Role of human metapneumovirus and respiratory syncytial virus in asthma exacerbations: where are we now? Clin Sci 131 (14): 1713-1721.

74. Seib, KL. (2017). Gonorrhoea vaccines: a step in the right direction, Lancet 390 (10102): 1567-1569.

75. Seib, KL, Jen, FEC, Scott, AL, Tan, A, and Jennings, MP. (2017). Phase variation of DNA methyltransferases and the regulation of virulence and immune evasion in the pathogenic Neisseria, Pathog Dis 75 (6): ftx080.

76. Shewell, LK, Jen, FEC, and Jennings, MP. (2017). Refinement of immunizing antigens to produce functional blocking antibodies against the AniA nitrite reductase of Neisseria gonorrhoeae, PLoS One 12 (8): e0182555.

77. Simone, MI, Mares, L, Eveleens, C, McCluskey, A, Pappin, BB, Kiefel, MJ, and Houston, TA. (2018). Back to (non-)Basics: An Update on Neutral and Charge Balanced Glycosidase Inhibitors, Mini Rev Med Chem: doi: 10.2174/1389557517666171002161325.

78. Srikhanta, YN, Gorrell, RJ, Power, PM, Tsyganov, K, Boitano, M, Clark, TA, Korlach, J, Hartland, EL, Jennings, MP, and Kwok, T. (2017). Methylomic and phenotypic analysis of the ModH5 phasevarion of Helicobacter pylori, Sci Rep 7 (1): 16140.

79. Srikhanta, YN, Gorrell, RJ, Power, PM, Tsyganov, K, Boitano, M, Clark, TA, Korlach, J, Hartland, EL, Jennings, MP, and Kwok, T. (2017). Methylomic and phenotypic analysis of the ModH5 phasevarion of Helicobacter pylori, Sci Rep 7: a16140.

80. Stanisic, DI, McCarthy, JS, and Good, MF. (2018). Controlled Human Malaria Infection: Applications, Advances, and Challenges, Infect Immun 86 (1): e000479-000417.


81. Stifter, SA, Matthews, AY, Mangan, NE, Fung, KY, Drew, A, Tate, MD, Soares da Costa, TP, Hampsey, D, Mayall, J, Hansbro, PM, Garcia Minambres, A, Eid, SG, Mak, J, Scoble, J, Lovrecz, G, de Weerd, NA, and Hertzog, PJ. (2017). Defining the distinct, intrinsic properties of the novel type I interferon, epsilon., J Biol Chem: doi: 10.1074/jbc.M1117.800755.

82. Taherzadeh, G, Zhou, Y, Liew, AW, and Yang, Y. (2017). Structure-based prediction of protein-peptide binding regions using random forest, Bioinformatics: doi: 10.1093/bioinformatics/btx1614.

83. Tan, A, Blakeway, LV, Bakaletz, LO, Boitano, M, Clark, TA, Jennings, MP, Peak, IR, and Seib, KL. (2017). Complete Genome Sequence of Moraxella catarrhalis Strain CCRI-195ME, Isolated from the Middle Ear, Genome Announc 5 (21): e00384-00317.

84. Taylor, A, Liu, X, Zaid, A, Goh, LYH, Hobson-Peters, J, Hall, RA, Merits, A, and Mahalingam, S. (2017). Mutation of the N-Terminal Region of Chikungunya Virus Capsid Protein: Implications for Vaccine Design, Mbio 8 (1): e01970-16.

85. Tharmarajah, K, Mahalingam, S, and Zaid, A. (2017). Chikungunya: Vaccines and Therapeutics, F1000Research 6: 2114.

86. Tiemeyer, M, Aoki, K, Paulson, J, Cummings, RD, York, WS, Karlsson, NG, Lisacek, F, Packer, NH, Campbell, MP, Aoki, NP, Fujita, A, Matsubara, M, Shinmachi, D, Tsuchiya, S, Yamada, I, Pierce, M, Ranzinger, R, Narimatsu, H, and Aoki-Kinoshita, KF. (2017). GlyTouCan: an accessible glycan structure repository, Glycobiology 27 (10): 915-919.

87. Vajjhala, PR, Ve, T, Bentham, A, Stacey, KJ, and Kobe, B. (2017). The molecular mechanisms of signaling by cooperative assembly formation in innate immunity pathways, Mol Immunol 86: 23-37.

88. Varki, A, Cummings, RD, Esko, JD, Stanley, P, Hart, GW, Aebi, M, Darvill, AG, Kinoshita, T, Packer, NH, Prestegard, JH, Schnaar, RL, and Seeberger, PH, (Eds.) (2017) Essentials of Glycobiology 3rd Ed, Cold Spring Harbor Laboratory Press.

89. Ve, T, Vajjhala, PR, Hedger, A, Croll, T, DiMaio, F, Horsefield, S, Yu, X, Lavrencic, P, Hassan, Z, Morgan, GP, Mansell, A, Mobli, M, O’Carroll, A, Chauvin, B, Gambin, Y, Sierecki, E, Landsberg, MJ, Stacey, KJ, Egelman, EH, and Kobe, B. (2017). Structural basis of TIR-domain-assembly formation in MAL- and MyD88-dependent TLR4 signaling, Nat Struct Mol Biol 24 (9): 743-751.

90. Whitney, PG, Makhlouf, C, MacLeod, B, Ma, JZ, Gressier, E, Greyer, M, Hochheiser, K, Bachem, A, Zaid, A, Voehringer, D, Heath, WR, Wagle, MV, Parish, I, Russell, TA, Smith, SA, Tscharke, DC, Gebhardt, T, and Bedoui, S. (2018). Effective priming of HSV-specific CD8+ T cells in vivo does not require infected dendritic cells, J Virol: doi: 10.1128/JVI.01508-01517. (Epub date 7 Nov 2017)

91. Wilson, JAC, Prow, NA, Schroder, WA, Ellis, JJ, Cumming, HE, Gearing, LJ, Poo, YS, Taylor, A, Hertzog, PJ, Di Giallonardo, F, Hueston, L, Le Grand, R, Tang, B, Le, TT, Gardner, J, Mahalingam, S, Roques, P, Bird, PI, and Suhrbier, A. (2017). RNA-Seq analysis of chikungunya virus infection and identification of granzyme A as a major promoter of arthritic inflammation, PLoS Pathog 13 (2): e1006155.

92. Wolf, S, Johnson, S, Perwitasari, O, Mahalingam, S, and Tripp, RA. (2017). Targeting the pro-inflammatory factor CCL2 (MCP-1) with Bindarit for influenza A (H7N9) treatment, Clin Translational Immunology 6: e135.

93. Woodberry, T, Loughland, JR, Minigo, G, Burel, JG, Amante, FH, Piera, KA, McNeil, Y, Yeo, TW, Good, MF, Doolan, DL, Engwerda, CR, McCarthy, JS, and Anstey, NM. (2017). Early Immune Regulatory Changes in a Primary Controlled Human Plasmodium vivax Infection: CD1c(+) Myeloid Dendritic Cell Maturation Arrest, Induction of the Kynurenine Pathway, and Regulatory T Cell Activation, Infect Immun 85 (6): e00986.

94. Xu, SC, Zhan, J, Man, BY, Jiang, SZ, Yue, WW, Gao, SB, Guo, CG, Liu, HP, Li, ZH, Wang, JH, and Zhou, YQ. (2017). Real-time reliable determination of binding kinetics of DNA hybridization using a multi-channel graphene biosensor, Nat Commun 8: a14902.

95. Yang, Y, Heffernan, R, Paliwal, K, Lyons, J, Dehzangi, A, Sharma, A, Wang, J, Sattar, A, and Zhou, Y. (2017) SPIDER2: A Package to Predict Secondary Structure, Accessible Surface Area, and Main-Chain Torsional Angles by Deep Neural Networks, In Prediction of Protein Secondary Structure (Zhou, Y, Kloczkowski, A, Faraggi, E, and Yang, Y, Eds.), pp 55-63.

96. Yu, JF, Dou, XH, Sha, YJ, Wang, CL, Wang, HB, Chen, YT, Zhang, F, Zhou, YQ, and Wang, JH. (2017). DisBind: A database of classified functional binding sites in disordered and structured regions of intrinsically disordered proteins, BMC Bioinformatics 18: 206.

97. Zaid, A, Gérardin, P, Taylor, A, Mostafavi, H, Malvy, D, and Mahalingam, S. (2018). Chikungunya Virus Arthritis: Implications of Acute and Chronic Inflammation Mechanisms on Patient Management, Arthritis Rheumatol: doi: 10.1002/art.40403. (Epub date 29 Dec 2017)

98. Zaid, A, Hor, JL, Christo, SN, Groom, JR, Heath, WR, Mackay, LK, and Mueller, SN. (2017). Chemokine Receptor-Dependent Control of Skin Tissue-Resident Memory T Cell Formation, J Immunol 199 (7): 2451-2459.

99. Zalucki, YM, and Jennings, MP. (2017). Signal peptidase I processed secretory signal sequences: Selection for and against specific amino acids at the second position of mature protein, Biochem Biophys Res Commun 483 (3): 972-977.


100. Zhang, XJ, Li, M, Lin, H, Rao, X, Feng, WX, Yang, YD, Mort, M, Cooper, DN, Wang, Y, Wang, YD, Wells, C, Zhou, YQ, and Liu, YL. (2017). regSNPs-splicing: a tool for prioritizing synonymous single-nucleotide substitution, Hum Genet 136 (9): 1279-1289.

101. Zhang, XX, Bernoux, M, Bentham, AR, Newman, TE, Ve, T, Casey, LW, Raaymakers, TM, Hu, J, Croll, TI, Schreiber, KJ, Staskawicz, BJ, Anderson, PA, Sohn, KH, Williams, SJ, Dodds, PN, and Kobe, B. (2017). Multiple functional self-association interfaces in plant TIR domains, Proc Natl Acad Sci U S A 114 (10): E2046-E2052.

102. Zhao, HY, Nyholt, DR, Yang, YH, Wang, JH, and Yang, YD. (2017). Improving the detection of pathways in genome-wide association studies by combined effects of SNPs from Linkage Disequilibrium blocks, Sci Rep 7: a3512.

103. Zhao, HY, Yang, YD, Lu, YT, Mort, M, Cooper, DN, Zuo, ZY, and Zhou, YQ. (2018). Quantitative mapping of genetic similarity in human heritable diseases by shared mutations, Hum Mutat 39 (2): 292-301. (Epub date 17 Oct 2017)

104. Zhou, B, Zhao, H, Yu, J, Guo, X, Dou, F, Hu, G, Cao, Z, Qu, Y, Yang, Y, Zhou, Y, and Wang, J. (2017). EVLncRNAs: a manually curated database for long non-coding RNAs validated by low-throughput experiments, Nucleic Acids Res: doi.org/10.1093/nar/gkx1677.

105. Zhou, Y, Kloczkowski, A, Faraggi, E, and Yang, Y, (Eds.) (2017) Prediction of Protein Secondary Structure Preface, Vol. 1484, Humana Press.

106. Zihad, SMNK, Saha, S, Rony, MS, Banu, H, Uddin, SJ, Shilpi, JA, and Grice, ID. (2018). Assessment of the laxative activity of an ethanolic extract of Bambusa arundinacea (Retz.) Willd. Shoot, J Ethnopharmacol 214: 8-12. (Epub date 5 Dec 2017)


New Grants in 20171. Sugar Research Australia Grant

Managing aspects of raw sugar quality in the Australian sugar industry Part 2 Von Itzstein,Mark; Houston,Todd Ashley; Haselhorst,Thomas Erwin; $899,446

2. ARC Future Fellowship Carbohydrate language changes in vertebrate-pathogen co-evolution Kolarich, Daniel $813,370

3. NHMRC - Project Grant Developing species-specific, structure-targeting peptides as a novel class of antibiotics Zhou,Yaoqi; Seib,Kate; Haselhorst,Thomas Erwin; Blanchard,Helen; Yang,Yuedong $607,967

4. NHMRC - Project Grant The role of capsid protein nucleolar localisation in chikungunya virus: implications for vaccine development Taylor,Adam $520,520

5. ARC Discovery Project New paradigms in glycointeractions Jennings,Michael Paul; Haselhorst,Thomas Erwin $475,163

6. ARC Discovery Project The molecular mechanism of action of bacterial epigenetic regulators Jennings,Michael Paul $439,130

7. NHMRC - Career Development Fellowship The role of glycans in arboviral disease; from immunomodulation to glycotherapeutic strategies Herrero, Lara $419,180

8. ARC Discovery Early Career Research Award (DECRA) Structural basis of paramyxovirus host cell entry Ve,Thomas $381,918

9. Advance Queensland Research Fellowship Old drug, new cause: fighting arthritis caused by Queensland viruses Rudd,Penny $300,000

10. Griffith University Infrastructure Grant A world-class bioanalytical facility: Circular dichroism spectrophotometer, surface plasmon resonance and enhanced protein production and purification Von Itzstein,Mark; Jennings,Michael Paul; Ulett,Glen Charles; Mahalingam,Suresh; Seib,Kate $264,871

11. National Institute of Health (NIH), USA GlyGen: Computational and Informatics Resources and Tools for Glycoscience Research Campbell,Matthew $54,551

12. Mizutani Foundation for Glycoscience Investigation of multiple novel lectin functions of human complement receptor 3 Jennings,Michael Paul $32,847

13. Glycomics Industry Fund (GIF) & Leidos, Inc Industry Partner Peptide-based PD-1 Inhibitors and Whole Blood-stage Parasite Malaria Vaccination Good,Michael Francis; Stanisic,Danielle $50,275

14. Childrens Hospital LA Cell Surface Glycan Differences as Biomarkers for leukemic B-cell Precursor Cells Packer,Nicki $16,951

15. Arthritis Australia Grant in Aid Investigating the use of Apremilast for the treatment of viral induced arthritides Rudd,Penny $15,000

16. GEOF-GUICS Grant & Biothera Industry Partner Development of novel immunotherapies for antibiotic resistant gonorrhea Seib,Kate $30,000

17. Griffith University New Researcher Grant A glycomics approach towards understanding Zika virus induced disease and discovering novel therapeutic targets Mutso,Margit $11,000

18. Griffith University New Researcher Grant Structure-based characterisation of enterovirus 71 binding specificity to host cells and development of virus entry inhibitors Bailly,Benjamin $9,000


Remarkable peopleOur staff hold a wide variety of knowledge and expertise.

We have more than 200 experts and support members contributing to our world-class research. Groundbreaking medical research requires exceptional people and an exceptional environment.

Institute for Glycomics Organisation

Director

Executive Support Officer

General Manager

Operations Managers

Facility Managers

Marketing and communications

Manager

Managment Commitees• Executive Group• Standing Committee• Research and Research

Training Committee• Education Committee• Safety Advisory Group

Boards• Board of Advice• Scientific and Business

Advisory Board

Business Manager

Administration Assistant

Executive Officer

Business Analyst

Facility Support Officer

Purchasing Officer

Finance Consultant (University central appointee)

Development Manager (University central appointee)

Senior Finance Consultant (University central appointee)

Deputy Director


Membership in 2017Dr Jodie Abrahams

Mr Haroon Ahmad

Mr Ammar Al-Kass

Ms Hanan Ahmed Najem Al-Nazal

Dr Kathirvel Alagesan

Ms Andreia Almeida

Prof Ralf Altmeyer

Mr Ali Ahmedah Amarah

Dr John Atack

Prof Anukumar Balakrishnan

Dr Benjamin Bailly

Dr Michael Batzloff

Prof Ifor Beacham

Dr Bernadette Bellette

Mr Callum Bennett

Prof Sue Berners-Price

Dr Jayaram Bettadapura

Mr Luke Blakeway

Prof Helen Blanchard

Mr Mohammad Bohari

Mr Patrick Bunn

Ms Ainslie Calcutt

Ms Nancy Callaghan

Dr Matthew Campbell

Ms Cindy Carroux

Ms Caroline Carstens

Mr James Carter

Dr Chih-Wei Chang

Ms Vimbaishe Chibanga

Mr Naveen Kumar Chintala Ramulu

Ms Nicola Cocroft

Mr Paul Connor

Dr Trent Conroy

Mr Oren Cooper

Prof Ross Coppel

Ms Fiona Crone

Dr Chris Davis

Dr Christopher Day

Dr Larissa Dirr

Mr Brad Dooley

Ms Jenni Dyason

Mr Jeff Dyason

Mr Daniel Earley

Dr Bassam Elgamoudi

Ms Jane Ellis

Dr Sharareh Eskandari

Ms Hadieh Eslampanah Seyedi

Mr Tanguy Eveno

Dr Arun Everest-Dass

Mr Jack Everson

Mr Ben Evert

Mr Dylan Farr

Prof Nicholas Farrell

Dr Raphael Enoque Ferraz de Paiva

Dr James Fink

Mr Joseph Freitas

Prof John Gerrard

Dr Ashwini Giddam

Mr Rob-Marc Go

Prof Michael Good

Dr Anil Gorle

Dr Darren Grice

Dr Patrice Guillon

Ms Barbara Hadley

Ms Danelle Hall

Dr Lauren Hartley-Tassell

Assoc Prof Thomas Haselhorst

Ms Lina Hayek

Mr Samuel Heddes

Dr Lara Herrero

Ms Mei Fong Ho

Mr Lucian Hollitt

Mrs Stephanie Holt

Dr Todd Houston

Dr Malik Hussain

Mr Brijesh Jakasaniya Aka Patel

Dr Freda Jen

Prof Michael Jennings

Dr Husen Jia

Dr Eloise Keeffe

Prof Soerge Kelm

Prof Natkunam Ketheesan

Dr Milton Kiefel

Dr Chandan Kishor

Assoc Prof Daniel Kolarich

Prof Victoria Korolik

Mrs Nina Kristensen

Ms Emma Langshaw


Ms Wai Suet Lee

Ms Linghui Li

Ms Elisa Lim

Mr Chi-Hung Lin

Dr Xiang Liu

Ms Xue Qin Liu

Dr Carie-Anne Logue

Ms Leanne Low

Mr Paul Madge

Dr Andrea Maggioni

Prof Suresh Mahalingam

Prof Johnson Mak

Mr Brody Mallard

Ms Veronika Masic

Ms Sonia Mckay

Ms Jamie-Lee Mills

Mr Rahul Mishra

Mr Tamim Mosaiab

Ms Helen Mostafavi

Ms Tsitsi Mubaiwa

Ms Joanna Musik

Dr Margit Mutso

Dr Tahria Najnin

Ms Elizabeth O’Hara

Mr Tiago Oliveira

Ms Victoria Ozberk

Prof Nicolle Packer

Ms Elina Panahi

Dr Manisha Pandey

Dr Mauro Pascolutti

Dr Ian Peak

Mr Gergely Pipa

Ms Jessica Poole

Mr Joshua Porter

Ms Jessica Powell

Dr Rajaratnam Premraj

Dr Gregory Rankin

Dr Michael Rolph

Ms Faith Rose

Ms Renee Ross

Dr Penny Rudd

Mr Hassan Sedaqat

Prof Peter Seeberger

Assoc Prof Kate Seib

Dr Evgeny Semchenko

Mr Lee Shaw

Dr Lucy Shewell

Dr Yun Shi

Mrs Skye Small

Mr Aloysious Ssemaganda

Dr Danielle Stanisic

Dr Erik Streed

Mr Aroon Supramaniam

Dr Taha

Dr Aimee Tan

Ms Olivia Tan Hui

Dr Adam Taylor

Ms Kothila Tharmarajah

Dr Robin Thomson

Mr Jamie Timms

Dr Catherine Tindal

Assoc Prof Joe Tiralongo

Dr Thomas Ve

Prof Mark von Itzstein

Dr Mario Waespy

Ms Jing Wang

Dr Wen Wang

Ms Judith Weber

Dr Julie Webster

Ms Stephanie Wilkinson

Dr Qiang Wu

Dr Peng Xiong

Dr Yuedong Yang

Dr Xing Yu

Dr Ali Zaid

Dr Yaramah Zalucki

Dr Mehfuz Zaman

Dr Jian Zhan

Mr Tongchuan Zhang

Mr Zhe Zhang

Dr Bailing Zhou

Dr Ning Zhou

Prof Yaoqi Zhou

60 other undergraduate and visiting researchers


Research highlights Vice Chancellor’s Research Excellence Awards

Summer Scholarships (for 2016/2017)Ryan ShibuKeith Kwan CheungEllen CrossmanPeta Coles

Honours Scholarship 2017Jack Everson – Sally & Warren von Bibra Honours ScholarshipStephanie Wilkinson – Glycomics Circle Honours ScholarshipJamie-Lee Mills - Glycomics Circle Honours ScholarshipRenee Ross - Glycomics Circle Honours Scholarship

2017 graduates19 May 2017, Dr Patrick Bunn, “Immune regulation during experimental visceral leishmaniasis”, supervised by Prof Michael Good, Dr Michael Batzloff and Dr Christian Engwerda

4 July 2017; Dr Catherine Tindal, “The synthesis and evaluation of carbohydrate-based probes of proteins involved in viral pathogenesis”, supervised by Prof Mark von Itzstein, Dr Robin Thomson & Dr Jeff Dyason

13 July 2017, Dr Tsitsi Mubaiwa, “The glycointeractome of Neisseria meningitidis”, supervisor by Prof Michael Jennings, Assoc Prof Kate Seib and Dr Lauren Hartley-Tassell

28 November 2017, Dr Mohammad Bohari, “Structure-based inhibitor design targeting Galectin-8”, supervisor by Prof Helen Blanchard & Dr Xing Yu”

The Vice Chancellor’s Research Excellence Awards celebrate the University’s research achievements and recognise individual researchers and research groups who have made outstanding contributions to both their discipline and to Griffith’s research profile. The award winners were:

Laboratory of Vaccines for the Developing World— Professor Michael Good, Dr Michael Batzloff, Dr Manisha Pandey, Dr Mehfuz Zaman, Dr Danielle Stanisic, Dr Sharareh Eskandari, Dr Ashwini Kumar Giddam, Ms Victoria Ozberk, Ms Emma Langshaw, Mrs Ainslie Calcutt, and Ms Jess Powell Institute for Glycomics Research Group or Team Award

Glycomics Research Excellence Awards 2017Prof Suresh Mahalingam – Research Leadership AwardDr Lara Herrero – Mid-Career/Senior Researcher AwardDr Benjamin Bailly – Early Career Researcher AwardProf Victoria Korolik – Research Supervision Award“The Fighting Infection & it’s Consequences” team led by Prof Mark von Itzstein – Research Group/Team AwardDr Tsitsi Diana Mubaiwa – Glycomics Director’s MedalAll awardees (except the Director’s Medal winner) are now being considered for the Vice Chancellors Research Excellence awards


Financial summary

Research Grant Funding

2016 2017

$8.363 million

$9.046 million

2016 2017

$5.562 million

$9.418 million

Industry & other support

Salary

2016 2017

$8.359 million

$9.449 million

2016 2017

$7.324 million

$8.843 million

Non salary


Plenary/Keynote/Invited Lectures in 20171. 31 January 2017; EMBO Global Exchange Lecture Course

– Malaria genomics and public health, Madurai, India; Prof Michael Good

2. 2-5 February 2017; 22nd Annual Lorne Proteomics Symposium, Lorne, Victoria; Assoc Prof Daniel Kolarich

3. 25 April 2017; Malaria Vaccine Symposium, Johns Hopkins University, Baltimore, US; Prof Michael Good

4. 20-27 April 2017; Characterization of post-transaltional modifications in cellular signalling, EMBO-Course, Odense, Denmark; Assoc Prof Daniel Kolarich

5. 2-5 May 2017; 8th International Conference on MIF and related cytokines, Dublin, Ireland; Prof Suresh Mahalingam

6. 6-9 May 2017; 12th Jenner Glycobiology and Medicine Symposium, Dubrovnik, Croatia; Assoc Prof Daniel Kolarich

7. 15-19 May 2017; Cold Spring Harbor Asia Conference on Membrane Proteins: Structure & Function, Suzhou, China; Assoc Prof Joe Tiralongo

8. 17 May 2017; The 10th Plotkin Lecture, Advanced Course of Vaccinology (ADVAC), Annecy, France; Prof Michael Good

9. 4-8 June 2017; 19th International Symposium on Recent Advances in Otitis Media Gold Coast, Australia; Assoc Prof Kate Seib

10. 12-16 June 2017; Beilstein Glycoinformatics Symposium 2017 and MIRAGE meeting, Berlin, Germany; Dr Matthew Campbell

11. 13-15 June 2017; Systems Glycomics, Beilstein Glyco-Bioinformatics Symposium 2017 and MIRAGE consortium annual meeting, Berlin; Germany; Assoc Prof Daniel Kolarich

12. 25-29 June 2017; Second International Convention Immunopharmacology - Vaccipharma 2017, Varadero, Cuba; Assoc Prof Kate Seib

13. 2-5 July 2017; The Australian Society for Microbiology, National Scientific Meeting Hobart, Australia; Assoc Prof Kate Seib

14. 2-5 July 2017; The Australian Society for Microbiology, National Scientific Meeting Hobart, Australia; Dr John Atack

15. 17-21 July 2017; International Union of Microbiological Societies, Singapore; Dr Lara Herrero

16. 28 July-5 August; 18th International Conference on Biological Inorganic Chemistry (ICBIC18), Florianopolis, Brazil; Prof Sue Berners-Price

17. 18-20 August 2017; Rotarians Against Malaria Annual Conference, Sydney, Australia; Dr Danielle Stanisic

18. 20-24 August 2017; 254th American Chemical Society National Meeting & Exposition, Washington DC, USA; Assoc Prof Thomas Haselhorst

19. 27 August-1 September 2017; GLYCO XXIV - 24th International Symposium on Glycoconjugates, Jeju Island, Korea; Prof Michael Jennings

20. 10-14 September 2017; CHRO2019 - 19th Campylobacters, Helicobacters and related organisms conference, Nantes, France; Prof Victoria Korolik

21. 2-5 October 2017; ComBio 2017, Adelaide, Australia; Assoc Prof Kate Seib

22. 16-20 October 2017; 20th Lancefield International Symposium on Streptococci and Streptococcal Diseases 2017, Denarau Island, Fiji; Prof Michael Jennings

23. 16-20 October 2017; 20th Lancefield International Symposium on Streptococci and Streptococcal Diseases 2017, Denarau Island, Fiji; Prof Michael Good

24. 31 October-3 November 2017, 12th Australian Influenza Symposium 2017 - Australian Respiratory Virology Meeting 2017, Melbourne, Australia; Dr Larissa Dirr

25. 2 November 2017; 2017 Skerman Lecture – University of Queensland, Brisbane; Prof Michael Jennings

26. 3 November 2017; NCIRS 20 Year Anniversary Showcase, Sydney, Australia; Prof Michael Good

27. 28 November-1 December 2017; 2017 Centre for Nanoscale BioPhotonics Annual Conference, Sydney/Melbourne - conference on The Golden Princess ship cruising between Sydney and Melbourne, Australia; Assoc Prof Daniel Kolarich

28. 29 November 2017; National Foundation for Medical Research and Innovation conference, Brisbane, Australia; Dr Chris Davis

29. 4-6 December 2017; International Union of Biochemistry and Molecular Biology - Special Meeting on “Frontiers in Glycoscience: Oncology, Taipei, Taiwan; Assoc Prof Joe Tiralongo

30. 4-6 December 2017; International Union of Biochemistry and Molecular Biology - Special Meeting on “Frontiers in Glycoscience: Oncology, Taipei, Taiwan; Assoc Prof Thomas Haselhorst

31. 10-14 December 2017; 12th International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy (ISPCC 2017), Sydney, Australia; Prof Sue Berners-Price

32. 7-9 December 2017; Virocon 2017 - 26th National Conference of the Indian Virological Society, Mangaluru, India; Prof Suresh Mahalingam


Remarkable supportThe supporters who make our discoveries possible. The Institute acknowledges the support of the Australian Government through funding from schemes including the National Health and Medical Research Council and the Australian Research Council, and from the Queensland Government.

• “Q” Clubs Buyers Group

• Palazzo Versace

• Gold Coast Titans Community Foundation

• Order of St John – Gold Coast Commandery

• John Penglis & Brenda Penglis

• John Barnes Foundation

• Ken & Noelene Tregeagle

• Southern Paradise Foundation

• Win Schubert AO

• Jock McIilwain DUniv & Beverly McIlwain

• Dennis & Shirley Croft

Honorary Fellows• Ms Roma Blair

• Mr Greg Dillon

• Mrs Mary Roosevelt

• Cr Dawn Crichlow OAM

• Jenny Wong, DUniv

• Warren von Bibra & Sally von Bibra

• The Hon Peter Beattie AC

• Mr John Penglis

• Mr James Wadham

• Mr Dennis Standfield

• Mr Bernard Ponting

• Mr Lex Bell OAM

• Emeritus Professor Graham Jones AM

• The Hon Sam Doumany

• Ms Beverly McIlwain

• The Hon Leneen Forde AC

Major Supporters• Queensland State Government

• Gold Coast City Council

• Honda Foundation

• Mark Carnegie

• John Singleton

• Lewis Land Group of Companies

• Theo Rossi & Mary Rossi OBE

• Jim Raptis, Raptis Group

• Amitabha Buddhist Association & Pureland Learning College

• Aston Milan

• Lilly Hwoo

• Jenny Wong, DUniv

• Macquarie Bank Foundation

• Alison Kearney & John Kearney, DUniv

• Conrad N. Hilton Foundation

• Warren von Bibra & Sally von Bibra

• S2F Pty Ltd

• Mayoress Community Benefit Fund Gold Coast

• Harry & Rhonda Triguboff

• Lorraine Dickinson

• Merchant Charitable Foundation

• Women in Racing Inc

• The Atlantic Philanthropies

• Mr Toshiaki Ogasawara

• Rotary Club of Southport

• Ms Beverly McIlwain

• Zarraffa’s Foundation

• Zarraffa’s Franchising Pty Ltd

• Steve Byrne & Sue Byrne

• BLIAQ Loving Care Group

• Larry Klinge & Penny Klinge

• Nick Moraitis

• Paul & Ildi Moraitis

• Geoffrey Thomas


institute for glycomics · 2019. 5. 20. · remarkable science cancer the australian centre for...

Documents